# US 2021/0275689 A1 · Processes of preparing mrna-loaded lipid nanoparticles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275689 A1
- Document ID: US20210275689A1
- Status: Published application
- Kind: A1
- Application number: 17/185,587
- Filed: 2021-02-25
- Published: 2021-09-09
- Earliest claimed: 2020-02-25
- Assignees: Translate Bio, Inc.
- Applicants: Translate Bio, Inc.
- Inventors: Shrirang Karve; Ashish Sarode; Frank DeRosa
- Web page: https://patentgrep.com/patent/US20210275689A1

## CPC

- A61K 9/1278: Post-loading, e.g. by ion or pH gradient
- A61K 48/0091: {Purification or manufacturing processes for gene therapy compositions}
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 38/1709: {from mammals}
- A61K 38/1816: {Erythropoietin [EPO]}
- A61K 38/443: {acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)}
- A61K 38/46: Hydrolases (3)
- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- A61K 38/53: Ligases (6)
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/6925: {the form being a microcapsule, nanocapsule, microbubble or nanobubble}
- A61K 48/0025: {wherein the non-active part clearly interacts with the delivered nucleic acid}
- A61K 48/0033: {the non-active part being non-polymeric}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- B01F 23/451: by injecting one liquid into another
- B01F 33/3017: {Mixing chamber}
- B01J 13/203: {Exchange of core-forming material by diffusion through the capsule wall}
- C12Y 114/16001: Phenylalanine 4-monooxygenase (1.14.16.1)
- C12Y 302/01022: Alpha-galactosidase (3.2.1.22)
- C12Y 304/21022: Coagulation factor IXa (3.4.21.22)
- C12Y 603/04005: Argininosuccinate synthase (6.3.4.5)
- A61K 48/0041: {the non-active part being polymeric}
- B01F 2101/22: Mixing of ingredients for pharmaceutical or medical compositions
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B01F: MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING (mixing paints B44D3/06)
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- C12Y: ENZYMES

## Abstract

The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a suspension of preformed lipid nanoparticles and mRNA.

## Claims

### Claim 1

A process of encapsulating messenger RNA (mRNA) in preformed empty lipid nanoparticles (LNPs), wherein the lipid component of the LNPs comprises or consists of a cationic lipid, a non-cationic lipid, a PEG-modified lipid, and optionally cholesterol and said process comprises the following steps:
adding a first volume of a solution comprising the mRNA to a suspension comprising the preformed empty LNPs such that a mixture comprising LNPs encapsulating the mRNA is formed;
adding one or more additional volumes of the solution comprising the mRNA to the mixture obtained in the preceding step until a desired molar ratio of cationic lipid to mRNA is achieved.

### Claim 2 (depends on 1)

The process of claim 1, wherein the addition of the first volume of the solution comprising the mRNA results in an at least 10-fold molar excess of cationic lipid to mRNA.

### Claim at position 3

3-8. (canceled)

### Claim 9 (depends on 1)

The process of claim 1, wherein a period of mixing occurs before addition of each of the one or more additional volumes of the solution comprising the mRNA.

### Claim at position 5

10-16. (canceled)

### Claim 17 (depends on 1)

The process of claim 1, wherein the first volume and the one or more additional volumes of the solution comprising the mRNA are added continuously.

### Claim at position 7

18-22. (canceled)

### Claim 23

A process of encapsulating messenger RNA (mRNA) in preformed empty lipid nanoparticles (LNPs), wherein the lipid component of the LNPs comprises or consists of a cationic lipid, a non-cationic lipid, a PEG-modified lipid, and optionally cholesterol and said process comprises the following steps:
adding a first volume of a suspension comprising the preformed empty LNPs to a solution comprising the mRNA such that a mixture comprising LNPs encapsulating the mRNA is formed;
adding one or more additional volumes of the suspension comprising the preformed empty LNPs to the mixture obtained in the preceding step until a desired molar ratio of cationic lipid to mRNA is achieved.

### Claim 24 (depends on 23)

The process of claim 23, wherein the addition of the first volume of the suspension comprising the preformed empty LNPs results in an approximately equimolar ratio of cationic lipid to mRNA.

### Claim at position 10

25-29. (canceled)

### Claim 30 (depends on 23)

The process of claim 23, wherein a period of mixing occurs before addition of each of the one or more additional volumes of the suspension comprising the preformed empty LNPs.

### Claim at position 12

31-37. (canceled)

### Claim 38 (depends on 23)

The process of claim 23 wherein the first volume and the one or more additional volumes of the suspension comprising the preformed empty LNPs are added continuously.

### Claim at position 14

39-43. (canceled)

### Claim 44 (depends on 38)

The process of claim 38, wherein the suspension comprising the preformed empty LNPs is at about 60° C. to about 70° C. and the solution comprising the mRNA is at ambient temperature.

### Claim at position 16

45-49. (canceled)

### Claim 50 (depends on 23)

The process of claim 23, wherein the empty LNPs are formed by mixing a lipid solution with an aqueous solution, wherein the lipid solution comprises a cationic lipid, a non-cationic lipid, and a PEG-modified lipid dissolved in ethanol.

### Claim at position 18

51-60. (canceled)

### Claim 61 (depends on 23)

The process of claim 23, wherein greater than about 90% of the preformed empty LNPs have a size ranging from 75-150 nm.

### Claim at position 20

62-74. (canceled)

### Claim 75

A method of manufacturing a lipid nanoparticle (LNP) composition, the method comprising:
mixing a first set of preformed empty lipid nanoparticles (LNPs) comprising a first cationic lipid, a first non-cationic lipid, a first PEG-modified lipid, and optionally cholesterol with mRNA under conditions that allow encapsulation of the mRNA;
combining the mRNA-encapsulating LNPs formed in step (a) with a second set of preformed empty LNPs comprising a second cationic lipid, a second non-cationic lipid, a second PEG-modified lipid, and optionally cholesterol, resulting in the LNP composition.

### Claim at position 22

76-81. (canceled)

### Claim 82 (depends on 75)

The method of claim 75, wherein the method further comprises a step of first mixing (i) the first cationic lipid, the first non-cationic lipid, the first PEG-modified lipid, and optionally cholesterol to form the first set of preformed empty LNPs prior to step (a) and/or (ii) the second cationic lipid, the second non-cationic lipid, the second PEG-modified lipid, and optionally cholesterol to form the second set of preformed empty LNPs prior to step (b).

### Claim at position 24

83-88. (canceled)

### Claim 89

A composition comprising a first set of mRNA-encapsulating lipid nanoparticles (LNPs) comprising a first cationic lipid, a first non-cationic lipid, a first PEG-modified lipid, and optionally cholesterol and a second set of empty LNPs comprising a second cationic lipid, a second non-cationic lipid, a second PEG-modified lipid, and optionally cholesterol,
wherein the first set of LNPs and the second set of LNPs are present at a ratio ranging from 20:1 to 1:20, from 10:1 to 1:10, from 5:1 to 1:5, from 3:1 to 1:3, or from 2:1 to 1:2.

### Claim 90 (depends on 89)

The composition of claim 89, wherein the first set of LNPs and the second set of LNPs have the same lipid formulations.

### Claim 91 (depends on 89)

The composition of claim 89, wherein the first set of LNPs and the second set of LNPs have different lipid formulations.

### Claim at position 28

92-98. (canceled)

### Claim 99 (depends on 89)

A method of delivering mRNA for in vivo protein expression, comprising administering to a subject a composition of claim 89.

### Claim 100 (depends on 89)

A method of treating a deficiency in a peptide, polypeptide or protein in a subject, wherein the method comprises administering to the subject the composition of claim 89, wherein the mRNA encodes the peptide, polypeptide or protein deficient in the subject.

### Claim at position 31

101-102. (canceled)

### Claim 103

A method of encapsulating messenger RNA (mRNA) into preformed empty lipid nanoparticles (LNPs) by mixing a first fluid comprising preformed empty LNPs and a second fluid comprising mRNA, wherein the lipid component of the LNPs comprises a cationic lipid, the method comprising:
mixing, for a first time period, the first fluid at a flow rate n1 with a first portion of the second fluid at a flow rate n2 to produce a mixed fluid having a first molar ratio of cationic lipid to mRNA;
mixing, for a second time period, the mixed fluid at a flow rate greater than n1 and a second portion of the second fluid at flow rate n2, such that the molar ratio of cationic lipid to mRNA of the resulting mixed fluid is at least 20% lower than the first molar ratio; and
repeating step (b) by increasing the flow rate of the resulting mixed fluid with each repeat until a desired molar ratio of cationic lipid to mRNA is reached.

### Claim at position 33

104-140. (canceled)

### Claim 141

An apparatus for encapsulating messenger RNA (mRNA) into preformed empty lipid nanoparticles (LNPs) by mixing a first fluid comprising preformed empty LNPs and a second fluid comprising mRNA, the apparatus comprising:
a first pump;
a second pump;
a mixing junction;
an intermediary vessel;
a first heat exchanger;
an arrangement of LNP conduits, configured to direct the first fluid to the mixing junction via the first pump;
an arrangement of mRNA conduits, configured to direct the second fluid to the mixing junction via the second pump, wherein the first and second fluids form a mixed fluid at the mixing junction;
a recycle loop, configured to:
direct the mixed fluid from the mixing junction to the first heat exchanger, and from the first heat exchanger to the intermediary vessel, and wherein the recycle loop is configurable to direct the mixed fluid from the intermediary vessel to:
the arrangement of LNP conduits upstream of the first pump; or the arrangement of mRNA conduits upstream of the second pump.

### Claim at position 35

142-163. (canceled)
